Pharmaceutical

BridgeBio secures $1.25bn for genetic therapy development

BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.

Jan 19, 2024 - 18:00
BridgeBio secures $1.25bn for genetic therapy development
BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.
Read the original article

Tags:

Previous Article

FDA grants fast track designation for Verastem’s NSCLC therapy

Next Article

argenx’s VYVDURA gains approval in Japan for gMG treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Instead of credible data, PDS Biotech delivers ‘results might get better, later’ promises

STAT+: Instead of credible data, PDS Biotech delivers ‘...

Jun 16, 2023

STAT+: Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach

STAT+: Novo acquires Inversago for up to $1 billion, sp...

Aug 11, 2023

Abortion funds run short of money as demand soars and donations fall

Abortion funds run short of money as demand soars and d...

Jan 24, 2024